Article Sidebar

Submitted
28 December 2017
Accepted
28 December 2017
Published
28 December 2017
Download
PDF
Statistic
Read Counter : 894 Download : 782

Main Article Content

Abstract

Urothelial Cell Carcinoma (UCC), also called transitional cell carcinoma of the bladder, is the most common malignancy in urinary tract. The prognosis of this disease is highly dependent on the histological grading at diagnosis. Fas/CD95 has a role in apoptotic process, whereas HSP70 has an antiapoptotic role. This study aimed to analyze the expression of Fas/CD95 and HSP70 in low grade and high grade urothelial cell carcinoma in the bladder. This was an analytic observational study with cross sectional approach. Population and sample were paraffin blocks of urothelial cell carcinoma in the Laboratory of Anatomic Pathology, Dr. Soetomo Hospital, Surabaya in the period of January 2011-December 2016. Each grading of urothelial cell carcinoma was randomly sampled. Immunohistochemystry with Fas/CD95 and HSP70 were performed. Expression of Fas/CD95 and HSP70 were assessed semiquantitatively. Expression of Fas/CD95 and HSP70  were analyzed using Mann-Whitney test and Spearman test. The results showed there was significant different in expression of Fas/CD95 and HSP70 in low and high grades in urothelial cell carcinoma. There was no significant correlation between the expression of Fas/CD95 and HSP70 in urothelial cell carcinoma.  As a conclusion, the role of CD95 and HSP70 expression can be useful as marker for the diagnosis, especially in the determination of the grade of differentiation.

Keywords

Fas/CD95 HSP70 urothelial cell carcinoma

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Heryanto, H., Kusumastuti, E. H., & Rahaju, A. S. (2017). ANALYSIS OF THE EXPRESSION OF FAS/CD95 AND HSP70 IN LOW AND HIGH GRADE UROTHELIAL CELL CARCINOMA OF THE BLADDER. Folia Medica Indonesiana, 53(4), 247–251. https://doi.org/10.20473/fmi.v53i4.7154
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Al-Bazzaz PH (2009). Stage of urinary bladder cancer at first presentation. Saudi Journal of Kidney Diseases and Transplantation 20, 628-631
  2. Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DM (2005). Molecular pathways in bladder cancer: part 1. BJU Int 95, 485-490
  3. Chatzitolios A, Venizelos I, Tripsianis G (2010). Prog-nostic significance of CD95, P53, and BCL2 express-ion in extranodal non-Hodgkin's lymphoma. Ann Hematol 89, 889–896
  4. Garg M, Kanojia D, Seth A, Kumar R, Gupta A, Surolia A, Suri A (2010). Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associ-ated with tumour progression and promotes migration and invasion. European Journal Of Cancer 46, 207-215
  5. Hall MC, Chang S, Balbagni G, et al (2007). Guideline for the management of nonmuscle invasive bladder cancer: (stages Ta, T1 and Tis): Update. American Urological Association.
  6. Jordan AM, Weingarten J, Murphy WM (1987). Tran-sitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer 60, 2766-74
  7. Kumar V, Abbas AK, Fausto N (2005) Cellular adap-tations, cell injury, and cell death. In: Robbins and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia, Elsevier, pp 25-32
  8. Peter ME, Hadji A, Murmann AE (2015) The role of CD95 and CD95 ligand in cancer. Macmillan Publish-ers Limited All rights reserved 1350-9047/15. Down-loaded from www.nature.com/cdd
  9. Prasad SM, DeCastro J, Steinberg GD (2011) Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urology, 1-12
  10. Strater J, Hinz U, Hasel C (2005) Impaired CD95 expression predisposes for recurrence in curatively re-sected colon carcinoma: clinical evidence for immu-noselection and CD95L mediated control of minimal residual disease. Gut 54, 661–665
  11. Tavassol F, Starke OF, Kokemuller H (2011). Prog-nostic significance of heat shock protein 70 (HSP70) in patients with oral cancer. Head & Neck Oncology 3, 10
  12. Yamana K, Bilim V, Hara N (2005). Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease pro-gression. British Journal of Cancer 93, 544 – 551
  13. Zorzi E, Bonvini P (2011) Inducible Hsp70 in the regulation of cancer cell survival: analysis of chape-rone induction, expression and activity. Cancers 3, 3921-3956. doi:10.3390/cancers3043921. www.mdpi. com/journal/cancers